Why Manufacturing Is the New Competitive Edge in Cell and Gene Therapy
About this episode
The episode discusses the competitive edge of manufacturing in cell and gene therapy with insights from Eytan Abraham.
In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Eytan Abraham, the Chief Commercial and Technology Officer at Minaris Advanced Therapies, to dive into how pharma companies can choose the right CDMO partners, the future of cell and gene therapy manufacturing, and the hard-earned lessons behind building sustainable, high-performance organizations in one of the most complex areas of medicine. Pharma Sessions provides general insights into the pharmaceutical and life science...
People in this episode
Host: Jonathan Kaskey
Guest: Eytan Abraham
Topics covered
- cell therapy
- gene therapy
- pharmaceutical manufacturing
- CDMO partners
- high-performance organizations
Keywords
- cell therapy
- gene therapy
- manufacturing
- CDMO
- pharmaceutical industry
Mentioned in this episode
Organizations: Minaris Advanced Therapies
More episodes of Pharma Sessions
- Where AI Delivers Real Value in Pharma Today with Emily Lewis
- How Medical Affairs Becomes the Connector with Sonia Talwar
- The Future of Healthcare with Dr. David Shulkin, former Secretary of the United States Department of Veterans Affairs Part 2
- The Future of Healthcare with Dr. David Shulkin, former Secretary of the United States Department of Veterans Affairs Part 1
- How AI Is Reshaping Pharma’s Commercial Operations with Punit Kumar
- Why Pharma products win or lose years before launch
Explore listener stats, chart rankings, contacts and more on the Pharma Sessions podcast page.